PMID-31927749 – Dulaglutide Systematic Review 21 RCTs
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials. Diabetes Obes Metab. 2020;22(4):626-636.
Quick Reference
| Property | Value |
|---|---|
| PMID | 31927749 |
| DOI | 10.1111/dom.13927 |
| Year | 2020 |
| Journal | Diabetes, Obesity and Metabolism |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | 21 RCTs, n=20,367 patients total |
| Peptide(s) Studied | Dulaglutide |
Key Findings
- Dulaglutide 0.75 mg reduced HbA1c by 0.29% and 1.5 mg by 0.55% more than active comparators
- Dulaglutide 1.5 mg was superior to active comparators in 5 of 6 AWARD trials for achieving HbA1c <7.0%
- Both doses produced significant weight loss vs. insulin and DPP-4 inhibitors
- Higher proportion of patients achieved HbA1c targets of <7.0% and <=6.5% with dulaglutide 1.5 mg
- Nausea was the most common adverse event but was generally transient
- No significant increase in major hypoglycemia when not combined with sulfonylureas or insulin
- GI side effects were dose-dependent and decreased over time
Study Design
Systematic review and meta-analysis of 21 RCTs from the AWARD clinical trial program and other published dulaglutide studies. Included both placebo-controlled and active-comparator trials (vs. insulin glargine, sitagliptin, exenatide, metformin, glimepiride). Endpoints included HbA1c change, weight change, proportion achieving glycemic targets, and adverse events.
Limitations
- Heterogeneity in comparator agents, background therapy, and trial duration
- Majority of trials were industry-sponsored
- Most trials were 26-52 weeks; limited long-term data beyond REWIND
- Meta-analysis may obscure population-specific effects
Clinical Relevance
This comprehensive meta-analysis confirms dulaglutide as an effective GLP-1 RA with consistent glycemic and weight benefits across diverse T2D populations and comparators. The large pooled sample (>20,000 patients) provides robust safety data. The favorable weight and glycemic profile compared to insulin makes it a strong option for T2D patients who also need weight management. Understanding dulaglutide's position in the GLP-1 RA landscape is essential for comparing it to newer agents like semaglutide and tirzepatide.
Related
#research #systematic-review #meta-analysis #evidence-level-I #metabolic #dulaglutide